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ABSTRACT
Background: Altering the temporal distribution of energy intake
(EI) and introducing periods of intermittent fasting (IF) exert
important metabolic effects. Restricting EI to earlier in the
day [early time-restricted feeding (eTRF)] is a novel type of
IF.
Objectives: We assessed the chronic effects of eTRF compared
with an energy-matched control on whole-body and skeletal muscle
insulin and anabolic sensitivity.
Methods: Sixteen healthy males (aged 23 ± 1 y; BMI 24.0 ± 0.6
kg·m−2) were assigned to 2 groups that underwent either 2 wk
of eTRF (n = 8) or control/caloric restriction (CON:CR; n = 8)
diet. The eTRF diet was consumed ad libitum and the intervention
was conducted before the CON:CR, in which the diet was provided to
match the reduction in EI and body weight observed in eTRF. During
eTRF, daily EI was restricted to between 08:00 and 16:00, which
prolonged the overnight fast by ∼5 h. The metabolic responses to a
carbohydrate/protein drink were assessed pre- and post-interventions
following a 12-h overnight fast.
Results: When compared with CON:CR, eTRF improved whole-
body insulin sensitivity [between-group difference (95% CI): 1.89
(0.18, 3.60); P = 0.03; η2p = 0.29] and skeletal muscle uptake
of glucose [between-group difference (95% CI): 4266 (261, 8270)
μmol·min−1·kg−1·180 min; P = 0.04; η2p = 0.31] and branched-
chain amino acids (BCAAs) [between-group difference (95% CI):
266 (77, 455) nmol·min−1·kg−1·180 min; P = 0.01; η2p = 0.44].
eTRF caused a reduction in EI (∼400 kcal·d−1) and weight loss
(−1.04 ± 0.25 kg; P = 0.01) that was matched in CON:CR
(−1.24 ± 0.35 kg; P = 0.01).
Conclusions: Under free-living conditions, eTRF improves whole-
body insulin sensitivity and increases skeletal muscle glucose and
BCAA uptake. The metabolic benefits of eTRF are independent of
its effects on weight loss and represent chronic adaptations rather
than the effect of the last bout of overnight fast. This trial was
registered at clinicaltrials.gov as NCT03969745. Am J Clin Nutr
2020;00:1–14.
Keywords: time-restricted feeding, free-living intervention, insulin
sensitivity, skeletal muscle, energy balance and metabolism, body
composition
Introduction
Most nutritional health research focuses on altering the
quantity and/or type of food consumed. Recent research suggests
that the temporal distribution of nutrient intake (chrononutrition)
can also play a role in mediating the health effects of a given
diet. For instance, restricting the daily energy intake (EI) window
to between 4 and 10 h, known as time-restricted feeding (TRF),
elicits favorable metabolic effects in rodents independently of
energy balance (1–3), which include protection against excessive
body weight gain in response to high-fat and high-sucrose diets,
reduced serum triglycerides, fasting insulin concentrations and
hepatic fat content, and improved glucose tolerance. However,
key differences in the adaptive metabolic response to fasting
between rodents and humans, including rates of hepatic glycogen
depletion (4, 5), may limit the translatability of these findings.
Studies investigating the effect of TRF in humans have
primarily focused on adaptations to resistance training (6–8)
and/or only examined fasting metabolism, energy balance, or
weight loss (9–11). In a feasibility study, overweight individuals
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underwent 16 wk of TRF, during which they were required
to reduce their daily eating duration to 10–12 h, resulting in
significant weight loss and improved levels of self-reported
sleep satisfaction and energy (12). Furthermore, improvements in
glucose tolerance after TRF have been shown in adults who were
overweight/obese (13–15). Short-term TRF has also been shown
to reduce appetite markers and increase 24-h fat oxidation rates in
overweight individuals (16). More recently, 12 wk of 10-h TRF
in individuals with metabolic syndrome improved markers of
cardiometabolic health, including blood pressure and circulating
lipids (17). Currently, there is a paucity of research in this area
using detailed metabolic measurements during the postprandial
period, which comprises most of the waking day. In addition,
no studies have examined the effect of TRF on skeletal muscle
metabolism, which plays an important role in the disposal of an
oral glucose load (18). Moreover, it is plausible that improved
skeletal muscle anabolic sensitivity may underpin the preferential
reductions in fat mass observed during TRF compared with an
energy-matched control diet in humans undertaking resistance
training (6).
An additional consideration is the optimal timing of the EI
window. Diurnal variations in metabolic function, including
glucose tolerance, were established several decades ago (19,
20). More recent, randomized crossover studies demonstrate
favorable acute metabolic responses to a meal consumed earlier
in the day (21, 22), and there is evidence suggesting chronically
shifting a greater proportion of EI to earlier in the day may also
be beneficial (23, 24). Early time-restricted feeding (eTRF) is
a dietary strategy combining these approaches by shifting EI to
earlier in the day and extending the length of the overnight fast. A
recent supervised, controlled feeding randomized controlled trial
found that 5 wk of eTRF improved whole-body insulin sensitivity
in individuals with prediabetes independently of weight loss
(15). However, metabolic responses were not compared after a
matched duration of fast, and the effects of eTRF in a free-living
setting have not yet been examined. This includes objectively
measured physical activity (PA) levels and glycemic variability
using continuous glucose monitors (CGMs).
The primary aim of this study was to compare the effects of
2 wk of free-living eTRF and an energy-matched (restricted)
control intervention on markers of whole-body and skeletal
muscle insulin and anabolic sensitivity in healthy young men.
Secondary aims were to assess the changes in body composition
and patterns of PA following 2 wk of intervention. It was
hypothesized that, compared with the control, eTRF will confer




This study was approved by the University of Nottingham
Faculty of Medicine and Health Sciences Research Ethics
Committee (Ref. No. 19–1705) and performed at the David
Greenfield Human Physiology Unit, University of Nottingham.
It was registered at clinicaltrials.gov as NCT03969745 and met
the regulations outlined in the Declaration of Helsinki. Informed
and written consent was obtained from all individuals prior to
enrollment in the study. A CONSORT flow diagram outlining the
study protocol is displayed in Figure 1.
Participants
This study was undertaken on 16 healthy young males [aged
23 ± 1 y; BMI (in kg·m−2) 24.0 ± 0.6; mean ± SEM].
Eligibility was assessed at a medical screening, which included
anthropometric measurements, blood pressure assessment, a 12-
lead electrocardiogram, and a blood sample for routine screening.
Inclusion criteria included men aged between 18 and 35 y
recruited from the university and general public, BMI between
18 and 27, and a moderately active PA level (PAL) between
1.6 and 1.99 (PAL = total energy expenditure/basal metabolic
rate). Exclusion criteria included any metabolic, endocrine, or
cardiovascular health condition; taking prescription medication
that may influence cardiovascular and/or metabolic function;
smoking; regular high alcohol consumption; irregular breakfast
consumption (<5 d/wk); and an Eating Attitudes Test–26
score >20.
Experimental design
Two experimental groups (matched for sex, age, BMI, and
PA) completed a 1-wk baseline period to establish participants’
habitual dietary and PA patterns before they underwent a 2-wk
dietary intervention [either eTRF or control/caloric restriction
(CON:CR)]. Since imposing restrictions on the length of the daily
EI window in free-living individuals consuming an ad libitum
diet has been shown to lead to a reduction in EI (25), the eTRF
study arm was completed first. This permitted weight loss and
the macronutrient composition and caloric content of dietary
intake in eTRF to be matched in the control group (CON:CR),
which was recruited for separately 9 mo after completion of
eTRF (Figure 1). Participants in both intervention groups were
instructed to maintain their habitual PA patterns throughout the
2-wk intervention.
Initially, resting metabolic rate (RMR) was obtained for all
participants following an overnight fast via indirect calorimetry
as described below under Pre- and Post-intervention Main
Experimental Trials. Participants in both groups also completed a
modified incremental treadmill protocol with indirect calorimetry
measurements (26) to improve the accuracy of free-living energy
expenditure (EE) estimates obtained from a combined heart
rate and accelerometer (Actiheart; CamNtech). Subjects were
also fitted with a subcutaneous glucose monitor (Freestyle
Libre; Abbott Diabetes Care), which recorded interstitial glucose
concentrations every 15 min, and were instructed to record all
EI using daily food diaries during a baseline week to establish
the habitual PA and dietary patterns, respectively. CGM and
food diaries were also recorded for the entire experimental
intervention periods and used to verify adherence to each eating
pattern.
Following the baseline week, participants visited the labora-
tory to assess their metabolic response to a carbohydrate (CHO)
and protein liquid test meal (see Pre- and Post-intervention Main
Experimental Trials below). From the next day, participants were
either asked to restrict their daily EI window to between 08:00
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Lifestyle (n = 8)
% of total days excluded:
• CGM: 15% in eTRF
• PA: 22% in eTRF
• Loss of data due to to 
malfunction of sensors
• Blood (n = 8)
• Muscle (n = 7) n = 1   
excluded due to 
insufficient tissue
Other analyses (n = 8)
• DXA: n = 1 excluded from 
eTRF due to equipment 
malfunction
Assessed for eligibility (n = 28)
Enrollment
Excluded (n = 12)
• Not meeting inclusion 
criteria (n = 8)
• Declined to participate 
(n = 4)
• Other reasons (n = 0)
Nonrandomized Allocation 
(2 groups recruited & tested 
sequentially 9 months apart)
Analysis
eTRF Group (n = 8) Recruited between 06/17–02/18
CON:CR Group (n = 8) Recruited between 11/18–05/19
Baseline (habitual) 
measurements (n = 8)
Baseline (habitual) 
measurements (n = 8)
Received CON:CR intervention (n = 8)
Received eTRF intervention (n = 8)
Lifestyle (n = 8)
% of total days excluded:
• CGM: 22% in CON:CR
• PA: 22% in CON:CR.
• Loss of data due to to 
malfunction of sensors
Blood (n = 8)
• No venous blood from 
n = 2 in CON:CR due to 
cannulation failure
Other analyses (n = 8)
• DXA: n = 1 excluded from 
CON:CR due to 
equipment malfunction
Analysis
Weight loss & Energy intake in eTRF was subsequently matched in CON:CR Group
FIGURE 1 CONSORT flow diagram of study protocol. CGM, continuous glucose monitoring; CON:CR, control/caloric restriction; DXA, dual-energy
X-ray absorptiometry; eTRF, early time-restricted feeding; PA, physical activity.
the temporal distribution of EI (CON:CR). In the former group,
participants were encouraged to not consciously alter the type
or quantity of food habitually consumed. In the CON:CR group,
participants were prescribed dietary plans and provided with all
food and beverages that matched the macronutrient composition
(45% CHO, 35% fat, and 20% protein) and caloric content in
eTRF. Participants in both groups were asked to restrict alcohol
consumption to ≤1 unit per day throughout the intervention.
Total daily EE for each participant was estimated using RMR
and personalized PAL estimated from accelerometry and heart
rate data. The deficit in EI in the CON:CR group was calculated
based on the average involuntary reduction observed in the eTRF
group and was scaled to the habitual total daily EE (as determined
above). By using objective measurements of PA and body mass
and composition throughout each intervention, any methodologic
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FIGURE 2 Schematic of experimental design and metabolic testing
protocol. B, vastus lateralis biopsy; BF, brachial artery blood flow;
BS, blood sampling; CGM, continuous glucose monitoring; CON:CR,
control/caloric restriction; CR, caloric restriction; DXA, dual-energy X-ray
absorptiometry; EI, energy intake; eTRF, early time-restricted feeding; IC,
indirect calorimetry; PA, physical activity.
intake deficits were minimized. After 2 wk, participants in both
groups visited the laboratory for a second main experimental trial
to undergo identical follow-up metabolic testing.
Pre- and post-intervention main experimental trials
Metabolic measurements were undertaken before and for
180 min after consumption of a CHO and protein drink. On
the day prior to each experimental, trial participants avoided
alcohol consumption and strenuous exercise. On each occasion,
an identical standardized evening meal was provided (45% CHO,
35% fat, 20% protein). Participants arrived at the laboratory the
next day at 08:00 after a standardized overnight (12-h) fast.
A schematic diagram of the experimental protocol followed is
outlined in Figure 2. Upon arrival, subjects provided a urine
sample before their body mass was recorded in light clothing.
Following this, a DXA scan (Lunar Prodigy DXA; GE Medical
Systems) was undertaken with subjects resting motionless in a
supine position.
Subjects then rested semisupine in a bed while two retrograde
cannulas were inserted, one guided by ultrasound (Aplio 300;
Toshiba) into a deep-lying branch of an antecubital vein of
the forearm and the other into a superficial hand vein of
the contralateral arm. The latter was kept in a hand-warming
unit maintained at 55◦C to obtain arterialized venous blood
samples that in our laboratory regularly achieve 96%–98%
oxygen saturation of hemoglobin. Cannulas were kept patent
using a saline drip, and samples were drawn simultaneously
at baseline (fasted) and then every 10 min for 3 h following
consumption of the liquid test meal. Brachial artery blood flow
(BFBA; expressed in mL·min−1) was measured immediately after
each blood sample using Doppler ultrasound. Rates of substrate
(S) uptake [in μmol·L−1 for glucose and nmol·L−1 for branched-
chain amino acids (BCAA)] across the forearm and glucose








arterialized glucose in mmol · L−1][
venous glucose in mmol · L−1]
)
(2)
Blood flow and substrate uptake were standardized relative
to lean forearm mass (in kg) determined by DXA
Vastus lateralis muscle biopsy specimens were obtained from
1 randomly assigned leg using the suction-modified Bergstrom
technique (27, 28) before and 180 min after consumption of the
drink in the eTRF intervention group only. Resting respiratory
exchange ratio (RER), substrate (CHO and fat) oxidation rates,
and EE were assessed before and 60 and 135 min after drink
consumption via indirect calorimetry using a flow-based dilution
canopy hood (Quark RMR; Cosmed) and values calculated using
the equations of Frayn (29) and Weir (30). A second urine
sample was collected at the end of the 3-h postprandial period.
Both the baseline and postprandial urine samples were measured
for volume and subsequently analyzed for the determination of
urinary urea nitrogen using an enzymatic kinetic assay (Randox
Cat# UR220), which allowed the calculation of nonprotein RER
and rates of substrate oxidation.
The liquid test meal was standardized according to body
weight (BW) and comprised 1 g·kgBW−1 dextrose, 0.4
g·kgBW−1 micellar casein protein (both from Bulk Powders),
and 2 g cocoa powder (Cadbury Bournville) mixed into
4 mL·kgBW−1 water and accompanied by an additional 2
mL·kgBW−1 of water. Participants were allocated 10 min to fully
consume the drinks, after which the 180-min postprandial period
started.
Blood analysis
For the determination of arterialized and deep venous blood
glucose concentrations (fasted and every 10 min postprandial),
aliquots of whole blood (0.5 mL) were rolled in sodium fluoride
microtubes for 3 min before simultaneous analysis using a YSI
2300 (YSI). Then, 2-mL aliquots of blood samples were collected
every 20 min into sodium heparin tubes containing EGTA-
glutathione (15 μL) and EDTA tubes with aprotinin (100 μL)
and were centrifuged immediately after collection at 4400 × g
for 10 min at 4◦C to obtain plasma. Another aliquot (3 mL)
was left to coagulate in spray-coated silica and polymer gel
tubes for 20–30 min before centrifugation at 4400 × g for 10
min at 4◦C to obtain serum. All blood samples were stored
at –80◦C until analyses. Concentrations of serum triglyceride
(TAG) and plasma free fatty acids (FFAs) were determined by
enzymatic colorimetric assays on a clinical chemistry analyzer
(ABX Pentra 400; Horiba). Serum insulin (cat. HI-014K; Merck
Millipore) and total plasma ghrelin (cat. GHRT89HK; Merck
Millipore) concentrations were determined using solid-phase
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technique (31). Total plasma concentrations of BCAAs were
determined spectrophotometrically using leucine dehydrogenase
(32), as described in Wilhelmsen et al. (33). Due to the inevitable
time elapsed between the 2 interventions, all analysis (other
than plasma ghrelin) was undertaken separately for eTRF and
CON:CR using appropriate controls to account for variability
between assays.
Skeletal muscle analysis
Muscle glycogen content was determined using a modified
version of the protocol established by Harris (34). Pyruvate
dehydrogenase complex (PDC) activity was determined using
the method described by Constantin-Teodosiu (35). PDC-related
acetyl-CoA formation rates were corrected for protein concen-
tration using the Pierce bicinchoninic acid assay (ThermoFisher
Scientific). Muscle BCAAs (leucine, isoleucine, and valine) and
their respective keto acids (KAs; ketoisocaproic acid, 2-keto-3-
methyl-valeric acid, and ketoisovaleric acid) were quantified by
hydrophilic interaction and reverse-phase liquid chromatography
(respectively) coupled to high-resolution mass spectrometry.
Powdered muscle samples were vigorously vortexed for 5 min
following the addition of 500 μL isopropanol (containing an
appropriate amount of internal standard):1 mol·L−1 KH2PO4
buffer (1:1 vol:vol), and then for a further 5 min following the
addition of 500 μL acetonitrile. Samples were then centrifuged
for 20 min at 14,000 × g at 4◦C. The supernatant was removed
and evaporated to dryness under vacuum centrifuge, and samples
were subsequently resuspended in 100 μL methanol:water (1:1
vol:vol) for LC-MS analyses. Absolute metabolite quantification
was achieved using an isotopically (uniformly labeled 13C)
internal standard method. Method validation in powdered skeletal
muscle and a proxy matrix (7.5% BSA) showed excellent
linearity (R2 > 0.99), accuracy and precision, and consistent
levels of recovery across all metabolites.
Outcomes
The primary outcomes of this study were the Matsuda index
of (whole-body) insulin sensitivity (36) and forearm (skeletal
muscle) glucose and BCAA uptake. Secondary outcomes were
changes in free-living components of energy balance, body
composition, and rates of substrate metabolism as assessed by
indirect calorimetry. Exploratory outcomes included indices of
glycemic variability under free-living conditions in both groups
and muscle analysis of glycogen content, PDC activity, and
BCAA and KA in response to feeding in the eTRF intervention
group only to assess potential underlying mechanisms that can
be exploited in future studies. The statistical power analysis
indicated that 8 participants were required to detect a 15%
improvement in postprandial whole-body insulin sensitivity (the
primary outcome) with a power of 80% at a 5% significance level
(37).
Data handing and statistical analysis
Food diaries were kept by all participants for 6 full days
during the baseline (habitual) period and for 13 d during
each treatment period. Dietary analysis of food diaries was
performed using Nutritics: (version 5.096; Nutritics Ltd, Ireland).
Duration of the daily EI window was calculated as the time
between the first and last entry in the food diary. CGMs were
also recorded for 6 full days during the baseline (habitual)
period and for 13 d during each treatment period. CGM data
were shifted back to the nearest 15-min time point, and days
with ≥20% missing data were excluded. Daily EE data from
the Actiheart were recorded at 1-min epochs and analyzed
using the “group calibration/individual HR + stress” model
as per the manufacturer’s instructions. This model limits the
weighting of HR data to the algorithm used to estimate EE
when the accelerometer detects little to no accompanying
movement. Any days with ≥10% lost data or ≥22.5% recovered
data were excluded from analyses. PALs were calculated as the
ratio of daily total EE to resting metabolic rate. Furthermore,
metabolic equivalent task (MET) values were used to estimate
times spent at different intensities of PA.
All data analysis was performed in GraphPad Prism (version
7.04; GraphPad Software), except for mixed-design 3-factor
ANOVA that was performed using SPSS Statistics (version 26;
IBM Corp.). All data are presented as means ± SEMs. Pre-
and post-intervention variables measured at a single time point
within an experimental group were compared using paired 2-
tailed t tests. Differences in metabolic variables between the 2
intervention groups (eTRF and CON:CR) were compared using
independent samples 2-tailed t tests (for variables measured at
baseline), a mixed-design 2-factor ANOVA (intervention group
× pre-post trials) for variables measured at a single time
point before (pre) and after (post) each intervention [including
incremental areas under the curve (iAUCs)], or a mixed-design 3-
factor ANOVA (intervention group × pre-post trials × sampling
time) for variables measured at multiple time points before and
after each intervention. Partial eta squared values (η2p) were cal-
culated to illustrate the effect size for statistically significant in-
tervention and interaction effects obtained when using ANOVA.
TABLE 1 Body mass and composition (assessed by DXA) before (pre) and after (post) 2 wk of eTRF or CON:CR1
Characteristic Pre-CON:CR Pre-eTRF Post-CON:CR Post-eTRF
Body mass, kg 77.68 ± 4.57 73.40 ± 2.97 76.44 ± 4.45∗∗ 72.36 ± 3.00∗∗
Fat mass, kg 17.17 ± 3.38 12.82 ± 1.36 16.43 ± 3.38 12.20 ± 1.44
Lean mass, kg 57.42 ± 2.55 56.63 ± 2.86 56.95 ± 2.56 56.11 ± 3.11
Android fat, kg 1.58 ± 0.34 1.06 ± 0.13 1.48 ± 0.32∗∗ 0.98 ± 0.13∗
Gynoid fat, kg 3.56 ± 0.64 2.65 ± 0.26 3.46 ± 0.64 2.47 ± 0.24∗
1Data are means ± SEMs; n = 7 per group, except for body mass (n = 8). Mixed-design 2-factor ANOVA revealed no differences between CON:CR and
eTRF in any of the indices but significant effects of time only on body mass (P = 0.0001), android fat (P = 0.0004), and gynoid fat (P = 0.02). Post hoc
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Cohen’s ds was used to quantify the effect size for statistically
significant comparisons between groups when using independent
samples t tests. All post hoc multiple comparisons following
ANOVA that showed significant effects were undertaken using




There were no differences in age (22 ± 1 compared with
24 ± 2 y; P = 0.23), BMI (24.0 ± 1.0 compared with
23.8 ± 0.5; P = 0.99), PAL (1.71 ± 0.06 compared with
1.74 ± 0.05; P = 0.65), or HOMA-IR (1.29 ± 0.20 compared
with 0.98 ± 0.13; P = 0.21) at baseline (habitual period) between
the eTRF and CON:CR groups, respectively.
Energy intake
The length of the daily EI window of participants’ habitual
diet was similar before the eTRF (739 ± 15 min) and CON:CR
(680 ± 27 min) interventions. This was shortened during
eTRF (412 ± 16 min) compared with CON:CR (701 ± 22
min) [between-group difference (95% CI): 289 (231, 347) min;
P = 0.00001; Cohen’s ds = 5.3]. Self-reported daily EI was
lower during eTRF compared with habitual EI (2318 ± 142
compared with 2722 ± 213 kcal; P = 0.01). Those self-reported
time windows were verified by examining the pattern of glucose
excursions using the 24-h CGM data. However, the relative
energy contribution from CHO, fat, and protein was unchanged
(post- compared with pre-eTRF; CHO, 44.7% ± 2.1% compared
with 42.5% ± 1.9%, P = 0.47; fat, 34.9% ± 1.7% compared
with 36.1% ± 1.1%, P = 0.59; protein, 20.0% ± 1.5% compared
with 19.9% ± 1.2, P = 0.96), and this was carefully replicated in
CON:CR.
Physical activity energy expenditure
PAL values were similar between eTRF and CON:CR both
before (1.71 ± 0.06 compared with 1.74 ± 0.05) and after
(1.74 ± 0.08 compared with 1.77 ± 0.09) the interventions
[between-group difference (95% CI): −0.03 (−0.21, 0.15)].
Similarly, there were no differences between intervention groups
in daily time spent at light (1.5 ≤ METs < 3), moderate
(3 ≤ METs < 6) or vigorous (≥6 METs) intensity of PA
(Supplemental Table 1).
Body weight and composition
There were no differences between CON:CR and eTRF in any
of the body composition indices at baseline (preintervention).
Body, lean, and fat mass responses to the interventions are
reported in Table 1 and were similar between eTRF and CON:CR
[between-group differences (95% CI): body mass, −0.20 (−1.14,
0.73) kg; lean mass, 0.06 (−1.54, 1.65) kg; fat mass, −0.13
(−1.56, 1.31) kg; android fat, −0.04 (−0.13, 0.05) kg; gynoid
fat, 0.07 (−0.16, 0.29) kg].














































































Intervention (Int):    P = 0.09
Pre-During (Trial):   P = 0.87
Int x Trial:                P = 0.88
FIGURE 3 Diurnal interstitial glucose concentrations during eTRF and
CON:CR. Data are means; n = 8 per group. The vertical dotted lines in
(A) and (B) represent the start and end of the eating window during eTRF.
CON:CR, control/caloric restriction; eTRF, early time-restricted feeding.
Mixed-design 2-factor ANOVA (intervention group compared with pre-post
trial) revealed no differences in any of the main effects or interaction between
groups in mean 24-h interstitial glucose concentrations (C).
Continuous glucose monitoring
Diurnal interstitial glucose profiles before and during eTRF
and CON:CR are displayed in Figure 3A and B. There
were no significant differences in mean 24-h interstitial glucose
concentrations between eTRF and CON:CR [between-group dif-
ference (95% CI): −0.28 (−0.61, 0.05) mmol·L−1] (Figure 3C).
However, there was a difference between interventions in 24-
h glycemic variability expressed as %CV (pre-eTRF 18.1 ± 1.0
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TABLE 2 Continuous glucose monitoring indices during 1 wk of habitual diet (pre) and during 2 wk of eTRF or CON:CR1
Characteristic Pre-CON:CR Pre-eTRF During CON:CR During eTRF
Mean glucose, mmol·L−1
08:00 to 20:00 5.58 ± 0.14 5.49 ± 0.19 5.53 ± 0.09 5.75 ± 0.13
20:00 to 08:00 5.34 ± 0.16 4.93 ± 0.18∗ 5.33 ± 0.07 4.58 ± 0.12∗∗∗
Glucose variability, %CV
08:00 to 20:00 13.6 ± 1.1 17.8 ± 0.7∗∗ 14.2 ± 1.2 18.6 ± 1.1∗∗
20:00 to 08:00 13.9 ± 1.0 16.7 ± 1.4 14.0 ± 0.8 13.5 ± 1.4
1Data are means ± SEMs; n = 8 for both CON:CR and eTRF. Separate mixed-design 2-factor ANOVA was performed for the 08:00 to 20:00 and 20:00
to 08:00 time windows that were not directly compared. The analysis revealed an intervention (group) effect (P = 0.003) between CON:CR and eTRF for
mean glucose during 20:00 to 08:00 only (post hoc: ∗P = 0.02 and ∗∗∗P = 0.001 from corresponding CON:CR) and an intervention effect (P = 0.003)
between CON:CR and eTRF for %CV during 08:00 to 20:00 only (post hoc: ∗∗P = 0.01 from corresponding CON:CR). CON:CR, control/caloric restriction;
eTRF, early time-restricted feeding.
compared with post-CON:CR 13.4 ± 1.0), which was driven by
higher values in eTRF than CON:CR both before and after the
intervention [between-group difference (95% CI): 5.1% (2.4%,
7.8%); main intervention effect P = 0.001; η2p = 0.55].
When separate subanalysis was performed on the 08:00 to
20:00 and 20:00 to 08:00 time windows, there were lower
mean glucose concentrations only in the latter window pre- and
post-eTRF compared with CON:CR [between-group difference
(95% CI): −0.58 (−0.92, −0.23) mmol·L−1; main intervention
effect P = 0.003; η2p = 0.47]. Furthermore, %CV was similar
between interventions during 20:00 to 08:00 but higher during
08:00 to 20:00 [between-group difference (95% CI): 4.3% (1.7%,
6.8%); main intervention effect P = 0.003; η2p = 0.48] in eTRF
compared with CON:CR (Table 2).
Fasting measurements
There were no differences in fasting arterialized blood
glucose [between-group difference (95% CI): −0.01 (−0.32,
0.30) mmol·L−1], plasma BCAAs [between-group difference
(95% CI): 46 (−14, 105) μmol·L−1], serum TAG [between-
group difference (95% CI): −0.05 (−0.25, 0.35) mmol·L−1],
or plasma FFA [between-group difference (95% CI): −0.02
(−0.21, 0.18) mmol·L−1] both before and after 2 wk of
eTRF or CON:CR (Table 3). However, fasting serum insulin
[between-group difference (95% CI): 29 (8, 49) ρmol·L−1; main
intervention effect P = 0.01; η2p = 0.39] and plasma ghrelin
[between-group difference (95% CI): 66 (20, 112) ρmol·L−1;
main intervention effect P = 0.01; η2p = 0.40] concentrations
were lower pre- and post-CON:CR, respectively, compared with
the eTRF. Resting metabolic rate was unchanged in response to
eTRF (pre 1829 ± 87 compared with post 1812 ± 62 kcal·d−1)
and CON:CR (pre 1937 ± 91 compared with post 1857 ± 70
kcal·d−1) with no differences observed between interventions.
RER and substrate oxidation rates
Significant interaction effects (intervention group × pre-
post trial) were observed on fasting nonprotein RER [between-
group difference (95% CI): −0.07 (−0.13, −0.01); interaction
effect P = 0.03; η2p = 0.28] and rates of CHO oxidation
[between-group difference (95% CI): −0.08 (−0.16, −0.01)
g·min−1; interaction effect P = 0.04; η2p = 0.26] but not fat
oxidation [between-group difference (95% CI): −0.01 (−0.03,
0.02) g·min−1] (Table 4). However, there were no differences in
postprandial rates of nonprotein RER [between-group difference
(95% CI): −0.01 (−0.05, 0.02)], CHO oxidation [between-
group difference (95% CI): −0.03 (−0.08, 0.02) g·min−1], or fat
oxidation [between-group difference (95% CI): −0.001 (−0.023,
0.020) g·min−1] between eTRF and CON:CR (Table 4).
Plasma FFA and serum TAG
In both eTRF and CON:CR, ingestion of the CHO and protein
drink rapidly suppressed circulating plasma FFA (main time
effect P = 0.0001; η2p = 0.84), but there were no significant
intervention or interaction effects (Figure 4A and B). Similarly,
serum TAG concentrations were lower after ingestion of the CHO
and protein drink (main time effect P = 0.0001; η2p = 0.63)
compared with fasting values, but no differences were shown
between eTRF and CON:CR (Figure 4C and D).
TABLE 3 Fasted arterialized metabolites before (pre) and after (post) 2 wk of eTRF or CON:CR1
Characteristic Pre-CON:CR Pre-eTRF Post-CON:CR Post-eTRF
Glucose, mmol·L−1 4.13 ± 0.09 4.03 ± 0.08 4.00 ± 0.13 4.08 ± 0.17
Serum insulin, ρmol·L−1 37 ± 5∗∗ 74 ± 12 43 ± 5 63 ± 7
Serum TAG, mmol·L−1 0.72 ± 0.10 0.81 ± 0.12 0.73 ± 0.10 0.73 ± 0.09
Plasma FFA, mmol·L−1 0.54 ± 0.04 0.51 ± 0.09 0.58 ± 0.09 0.58 ± 0.06
Plasma BCAA, μmol·L−1 207 ± 20 263 ± 18 222 ± 21 257 ± 23
Plasma total ghrelin, ρmol·L−1 229 ± 19 282 ± 15 203 ± 21∗∗ 281 ± 15
1Data are means ± SEMs; n = 8 per group. Mixed-design 2-factor ANOVA revealed an intervention (group) effect (P = 0.01) for both insulin and
ghrelin (post hoc ∗∗P = 0.01 from corresponding eTRF time point). BCAA, branched-chain amino acid; CON:CR, control/caloric restriction; eTRF, early
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TABLE 4 RER and rates of substrate metabolism before (fasted) and in response to postprandial (PP) consumption of a CHO and protein drink before (pre)
and after (post) eTRF and CON:CR1
Pre-CON:CR Pre-eTRF Post-CON:CR Post-eTRF
Characteristic Fasted PP Fasted PP Fasted PP Fasted PP
RER 0.79 ± 0.03 0.87 ± 0.03 0.75 ± 0.02 0.85 ± 0.02 0.75 ± 0.01 0.87 ± 0.01 0.77 ± 0.02 0.85 ± 0.01
CHOox, g·min–1 0.11 ± 0.03 0.21 ± 0.03 0.04 ± 0.02 0.18 ± 0.02 0.06 ± 0.02 0.20 ± 0.02 0.08 ± 0.02 0.16 ± 0.02
FATox, g·min–1 0.10 ± 0.02 0.07 ± 0.02 0.11 ± 0.01 0.06 ± 0.01 0.11 ± 0.01 0.06 ± 0.01 0.09 ± 0.01 0.06 ± 0.01
1Data are presented as means ± SEMs; n = 8 per group. All PP values refer to the average of measurements throughout the 3-h postprandial period.
Separate mixed-design 2-factor ANOVA (intervention group × pre-post trials) for fasted and PP data revealed significant interactions for fasted RER
(P = 0.03) and CHOox (P = 0.04) but no FATox (P = 0.08), whereas no differences were observed between eTRF and CON:CR in any of the PP indices.
CHOox, carbohydrate oxidation rates; CON:CR, control/caloric restriction; eTRF, early time-restricted feeding; FATox, fat oxidation rates; PP, 3-h
postprandial period following the test meal consumption; RER, nonprotein respiratory exchange ratio.
Blood glucose, serum insulin, and whole-body insulin
sensitivity
In both interventions, circulating glucose and insulin concen-
trations increased in response to ingestion of the CHO and protein
drink. However, a significant interaction effect (intervention
group × pre-post trial × sampling time) on circulating glucose
was observed (P = 0.01; η2p = 0.13), with values increasing
post-CON:CR and decreasing post-eTRF compared with their
respective preintervention trials (Figure 5A and B). Accordingly,
an interaction effect (intervention group × pre-post trial) was
also observed between intervention groups for the glucose iAUC
[between-group difference (95% CI): 93 (11, 176) mmol·L−1·180























Intervention (Int): P = 0.34
Pre-Post (Trial):   P = 0.88
Time:        P = 0.00
Int x Trial:             P = 0.40
Int x Time:            P = 0.35
Trial x Time:        P = 0.29
Int x Trial x Time: P = 0.14

























































Intervention (Int): P = 0.82
Pre-Post (Trial):   P = 0.16
Time:        P = 0.00
Int x Trial:             P = 0.18
Int x Time:            P = 0.59
Trial x Time:        P = 0.21
Int x Trial x Time: P = 0.98
Pre eTRF Pre CON:CR Post eTRF Post CON:CR 
FIGURE 4 (A, B) Arterialized plasma FFA and (C, D) serum TAG in response to consumption of a liquid test meal before (pre) and after (post) 2 wk of
dietary intervention. All data are means ± SEMs; n = 8 per group. P values displayed in text boxes refer to mixed-design 3-factor ANOVA (intervention group
× pre-post trial × sampling time) performed for the entire postprandial period. CON:CR, control/caloric restriction; eTRF, early time-restricted feeding; FFA,
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Int x Trial:             P = 0.03  
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Intervention (Int): P = 0.20
Pre-Post (Trial):   P = 0.94
Time:        P = 0.00
Int x Trial:             P = 0.12
Int x Time:            P = 0.63
Trial x Time:        P = 0.06
Int x Trial x Time: P = 0.01










































Intervention (Int): P = 0.21
Pre-Post (Trial):   P = 0.40
Time:        P = 0.00
Int x Trial:             P = 0.02
Int x Time:            P = 0.66
Trial x Time:        P = 0.88
Int x Trial x Time: P = 0.09






























Intervention (Int): P = 0.18
Pre-Post (Trial):   P = 0.97
Int x Trial:             P = 0.03  



























Intervention (Int): P = 0.54
Pre-Post (Trial):   P = 0.54
Int x Trial:             P = 0.04  
FIGURE 5 Indices of whole-body insulin sensitivity: (A, B) arterialized blood glucose, (C) iAUC for glucose, (D, E) arterialized serum insulin, (F) iAUC
for insulin, and (G) Matsuda index of insulin sensitivity in response to consumption of a liquid test meal before (pre) and after (post) 2 wk of dietary intervention.
All data are means ± SEMs; n = 8 per group. P values displayed in text boxes refer to mixed-design 3-factor ANOVA (intervention group × pre-post trial ×
sampling time) performed for the entire postprandial period (A, B, D, and E) and mixed-design 2-factor ANOVA (intervention group × pre-post trial) performed
for iAUC data (C, F). CON:CR, control/caloric restriction; eTRF, early time-restricted feeding; iAUC, incremental area under the curve; M-ISI, Matsuda index
of insulin sensitivity.
min; main interaction effect P = 0.03; η2p = 0.29], which
decreased after eTRF and increased after CON:CR compared
with their respective preintervention concentrations (Figure 5C).
Significant interaction effects (intervention group × pre-post
trial) were observed for both the serum insulin concentrations
(P = 0.02; η2p = 0.34) and iAUC [between-group difference
(95% CI): 9697 (248, 19,146) ρmol·L−1·180 min; main interac-
tion effect P = 0.04; η2p = 0.26] across the entire postprandial
period, with values decreasing after eTRF and increasing
after CON:CR compared with their respective preintervention
concentrations (Figure 5D–F).
The Matsuda insulin sensitivity index (M-ISI), a composite
index of hepatic and peripheral insulin sensitivity, improved
after 2 wk of eTRF but declined in the CON:CR group as
indicated by a significant interaction effect [between-group
difference (95% CI): 1.89 (0.18, 3.60); intervention group ×
pre-post trial interaction effect P = 0.03; η2p = 0.29] shown in
Figure 5G.
Skeletal muscle insulin sensitivity
In both interventions, brachial artery blood flow and arteriove-
nous (AV) glucose differences increased in response to ingestion
of the CHO and protein drink, but no significant intervention
or interaction effects were observed (Figure 6A–D). Brachial
blood flow was similar post-CON:CR but tended to be lower post-
eTRF compared with preintervention trials (interaction effect for
intervention group × pre-post trial × sampling time, P = 0.06;
η2p = 0.12) (Figure 6C and D).
Significant interaction effects (intervention group × pre-
post trial) were observed for the forearm (muscle) glucose
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FIGURE 6 (A, B) Arteriovenous glucose differences, (C, D) brachial artery blood flow, and (E–G) forearm (skeletal muscle) glucose uptake in response to
consumption of a liquid test meal before (pre) and after (post) 2 wk of dietary intervention. Data are means ± SEMs. n = 8 for eTRF and n = 6 for CON:CR.
Blood flow and glucose uptake are standardized relative to lean forearm mass (in kg) determined by DXA. P values displayed in text boxes refer to mixed-design
3-factor ANOVA (intervention group × pre-post trial × sampling time) performed for the entire postprandial period (A–F) and mixed-design 2-factor ANOVA
(intervention group × pre-post trial) performed for iAUC data (G). CON:CR, control/caloric restriction; eTRF, early time-restricted feeding.
difference (95% CI): 4266 (261, 8270) μmol·min−1·kg−1·180
min; P = 0.04; η2p = 0.31] across the entire postprandial
period, which increased post-eTRF and decreased post-CON:CR
compared with their respective preintervention concentrations
(Figure 6E–G). Glucose extraction was unaffected by eTRF
(pre 11% ± 2% compared with post 15% ± 3%) and CON:CR
(pre 17% ± 2% compared with post 15% ± 3%) with no
significant difference observed between interventions [between-
group difference (95% CI): −7% (−15%, 2%); interaction effect
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FIGURE 7 (A, B) Arteriovenous plasma BCAA differences and (C–E) forearm (skeletal muscle) BCAA uptake in response to consumption of a liquid
test meal before (pre) and after (post) 2 wk of dietary intervention. Data are means ± SEMs. n = 8 for eTRF and n = 6 for CON:CR. Forearm BCAA uptake is
expressed relative to lean forearm mass (in kg) determined by DXA. P values displayed in text boxes refer to mixed-design 3-factor ANOVA (intervention group
× pre-post trial × sampling time) performed for the entire postprandial period (A–D) and mixed-design 2-factor ANOVA (intervention group × pre-post trial)
performed for incremental area under the curve data (E). BCAA, branched-chain amino acids; CON:CR, control/caloric restriction; eTRF, early time-restricted
feeding.
Plasma BCAA concentrations
In both intervention groups, AV BCAA differences increased
after ingestion of the CHO and protein drink. However, an
interaction effect (intervention group × pre-post trial) was
observed, with higher AV BCAA differences post-eTRF and
lower values post-CON:CR compared with their respective
preintervention trials (P = 0.001; η2p = 0.59; Figure 7A and B).
A similar pattern of interaction (intervention group × pre-post
trial) was shown in BCAA forearm (muscle) uptake (P = 0.01;
η2p = 0.64) and iAUC [between-group difference (95% CI): 266
(77, 455) nmol·min−1·kg−1·180 min; P = 0.01; η2p = 0.44]
across the entire postprandial period, which increased post-eTRF
and decreased post-CON:CR compared with preintervention
trials (Figure 7C–E).
Muscle glycogen, PDC activity, and BCCA content
We next sought to explore the intramuscular fate of the
increased skeletal muscle glucose and BCAA uptake after
eTRF. Muscle glycogen content, an index of nonoxidative
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TABLE 5 Skeletal muscle analysis before (pre) and 2 wk after (post) eTRF1
Pre-eTRF Post-eTRF
Characteristic 0 min 180 min 0 min 180 min
BCAA, μmol·kgDW−1 2059 ± 150 1839 ± 122 1934 ± 132 2015 ± 171
KA, μmol·kgDW−1 56.4 ± 6.2 44.6 ± 8.3 58.0 ± 8.2 55.7 ± 12.0
Glycogen, mmol glycosyl units·kgDW−1 359 ± 25 360 ± 36 382 ± 48 380 ± 43
PDC activity, nmol·mg protein−1· min−1 4.17 ± 0.64 4.41 ± 0.61∗∗ 3.77 ± 0.34 5.42 ± 0.74∗∗
1Data are means ± SEMs; n = 7. Mixed-design 2-factor ANOVA revealed no intervention or interaction effects for muscle BCAA (P = 0.89 and
P = 0.10, respectively), KA (P = 0.53 and P = 0.37, respectively), glycogen (P = 0.57 and P = 0.96, respectively), or PDC (P = 0.69 and P = 0.30,
respectively). A time effect (∗∗P = 0.002 from respective 0 min) was observed for PDC only. BCAA, branched-chain amino acid (sum of leucine, isoleucine,
and valine); DW, dry weight; eTRF, early time-restricted feeding; KA, branched-chain keto acids (sum of ketoisocaproic, 2-keto-3-methyl-valeric, and
ketoisovaleric acids); PDC, pyruvate dehydrogenase complex.
remained unchanged [within-group difference (95% CI): 21
(−65, 108) mmol glycosyl units·kg−1 dry weight] 180 min
postconsumption of the CHO and protein drink (Table 5).
PDC activity, the rate-limiting step in muscle glucose ox-
idation, increased after ingestion of the CHO and protein
drink [fast-fed difference (95% CI): 0.94 (0.53, 1.36) nmol·mg
protein−1·min−1; P = 0.002; η2p = 0.84] but no difference was
found between pre- and post-eTRF [within-group difference
(95% CI): 0.30 (−1.43, 2.04) nmol·mg protein−1·min−1]. Fasting
and postprandial muscle BCAA (sum of leucine, isoleucine,
and valine) concentrations were not significantly different
post-eTRF compared with pre-eTRF [within-group difference
(95% CI): 301 (−62, 664) μmol·kg−1 dry weight; interaction
effect P = 0.10; η2p = 0.21] (Table 5). Fasting and post-
prandial muscle branched-chain KA (sum of ketoisocaproic,
2-keto-3-methyl-valeric, and ketoisovaleric acids) concentra-
tions were unaffected by the eTRF intervention [within-group
difference (95% CI): 6 (−28, 16) μmol·kg−1 dry weight]
(Table 5).
Discussion
The present study shows that under free-living conditions,
2 wk of eTRF improves whole-body insulin sensitivity and
increases postprandial skeletal muscle nutrient (glucose and
amino acids) uptake in healthy young men. Importantly, our
results suggest these beneficial effects are independent of the
changes in body composition and energy balance elicited by
a reduction in free-living EI during eTRF. Moreover, unlike
previous research (15), they represent chronic adaptations to
eTRF, rather than the acute effect of the last bout of prolonged
overnight fast, as the duration of fast prior to metabolic testing
was standardized to habitual levels.
The improvement in whole-body insulin sensitivity is ev-
idenced by the lower postprandial glycemic and insulinemic
responses and higher M-ISI in response to consumption of the
CHO and protein drink in eTRF compared with CON:CR. This
extends recent findings on overweight men with prediabetes (15)
to a healthier population. In contrast, no reductions in fasting
insulin were shown, which is in line with previous observations
made in males with obesity after a standardized fast (13).
However, 8 wk of TRF have previously shown to lower fasting
insulin in healthy resistance-trained males (6), suggesting 2 wk
may have been insufficient to detect a difference in fasting insulin.
Incorporating protein and dextrose into the oral liquid
test challenge permitted simultaneous insight into postprandial
skeletal muscle glucose and BCAA uptake, as indices of muscle
insulin and anabolic sensitivity, respectively. As no significant
differences in blood flow to the muscle were observed between
interventions, the elevated glucose uptake in the postprandial
period of the eTRF trial (which was particularly prominent
in the initial 90 min of it) could be accounted for by
improved efficiency of glucose extraction. This is interesting,
considering postprandial insulin concentrations were lower in
eTRF compared with CON:CR.
The increased skeletal muscle glucose uptake after eTRF,
compared with CON:CR, was not accompanied by higher whole-
body postprandial CHO oxidation rates. Muscle glycogen content
was also unchanged, suggesting nonoxidative glucose disposal
was similar. Muscle PDC activation, the rate-limiting step in
muscle glucose oxidation, was similar in the basal (fasted)
condition and increased in response to consumption of the liquid
test meal in both trials. More pronounced differences in PDC
activation, and hence muscle glucose oxidation, may have been
evident if the postprandial muscle biopsy was obtained earlier
than 180 min, when glucose uptake and insulin concentrations
were elevated.
Forearm BCAA uptake also increased in response to feeding
after 2 wk of eTRF compared with CON:CR, which could be
an adaptive mechanism to potentiate the anabolic response to
protein ingestion as the body adapts to a shorter EI window.
This may partially explain previous observations that TRF
promotes improved retention of lean body mass during weight
loss in response to resistance training (6), although this was not
replicated in this study presumably due to its short-term nature
and limited weight loss incurred. Increased uptake of plasma
BCAA by skeletal muscle after eTRF in the present study is
supported by our data showing a trend (P = 0.10) for increased
intramuscular BCAA content after feeding. The metabolic fate
(synthesis or oxidation) of these BCAAs remains unknown,
although we observed no changes in their keto acids after feeding,
which suggests a potential anabolic response. Future studies
should address the efficacy of eTRF as a nutritional strategy to
better preserve the protein synthetic response to a protein-rich
meal and hence lean body mass under conditions of weight loss
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Both prolonging the daily fast and shifting food intake to
earlier in the day likely contributed to the underlying metabolic
improvements after eTRF. Diurnal metabolic responses to
nutrients are influenced by the circadian system, and glucose
tolerance is higher earlier in the day (19–22). Although different
EI windows (early compared with late TRF) were not directly
compared in the present study, we postulate that chronically
shifting nutrient intake to earlier in the day may have beneficial
metabolic effects (15, 23–25). Although similar weight loss was
induced by both interventions in the present study, there were no
obvious metabolic benefits associated with the CON:CR group.
The reasons are unclear but could relate to the short-term nature
and limited body weight loss incurred in young physically active
individuals that is unlikely to alter metabolic health.
Adherence to the eTRF protocol was high, with only 1
reported eating event outside of the stipulated EI window.
This is further supported by the pronounced differences in
glycemic profiles between CON:CR and eTRF, with lower mean
glucose values evident between 20:00 and 08:00 (reflecting
the longer overnight fast) and higher variability during 08:00
and 20:00 in eTRF (reflecting the shorter EI window). To our
knowledge, only 1 other study (13) has compared free-living
glucose concentrations during a habitual diet and eTRF. They
also found no change in mean 24-h glucose but a reduction in
fasting glucose concentration, defined as the time between 4 h
after consumption of the last meal of the day until the time of the
first meal of the next day. These findings are broadly comparable
to the 20:00 to 08:00 fasting window used in the present study
and in agreement with our findings of lower mean glucose values
during that period in eTRF.
In line with previous research, imposing restrictions on the
length of the daily EI window in a free-living setting leads to an
involuntary reduction in EI (9, 25, 38). In the present study, this
was estimated to be ∼400 kcal·d−1 and, in the absence of changes
in objectively quantified PA levels, led to a negative energy
balance that resulted in a mean body mass loss of 1.04 ± 0.25
kg over the 2-wk eTRF intervention period. Previous studies
objectively measuring PA during TRF showed no changes but
were conducted on adults who were overweight/obese, with low
baseline PA levels (13, 38). The present study extends these
findings to a more physically active population. This contrasts
with reductions in PA observed during Ramadan (39, 40) and
likely reflects the chronobiologically opposing EI windows used.
A major strength of this study is the comparable weight loss
elicited in a control group matched for age, BMI, and PA. This
was achieved by prescribing a diet matched for macronutrient
composition, and importantly, participants did not alter their
temporal distribution of EI during CON:CR. Together, these
results suggest that the metabolic improvements observed after
eTRF are independent of the energy imbalance and small but
significant amount of weight lost elicited by a reduction in free-
living EI. One limitation of the present study is that only healthy
men were recruited, and there may be sex-based differences in
responses to intermittent fasting (41). Other limitations include
the short-term study duration and the use of self-reported
energy intake data to prescribe an energy-matched diet for the
CON:CR group. However, by using objective measurements
of PA and body composition, any methodologic limitations of
relying on food diaries for the estimation of dietary intake
deficits were minimized. Those measurements also confirmed
that the participants complied with the requirements of the study,
including the voluntary energy deficit imposed on the participants
in the CON:CR group.
In summary, the present study highlights skeletal muscle as
an important tissue modulating the beneficial effects of eTRF
on postprandial insulin and anabolic sensitivity in healthy men.
Although improvements in insulin sensitivity are likely more
relevant to clinical populations at an increased susceptibility
to metabolic disease(s), even in healthy individuals, insulin
sensitivity is an independent predictor of future cardiovascular
disease (42, 43). Our results suggest that eTRF would lead to
a natural reduction to EI and augment the insulin-sensitizing
effect of the accompanying weight loss. This suggests eTRF
has potential applications as an alternative to calorie counting
and may provide a simplistic, accessible dietary intervention.
However, larger-scale research studies are necessary to address
its feasibility in the longer term. While research suggests eTRF
may confer additional metabolic benefits over other intermittent
fasting approaches, direct comparisons between different eating
windows are necessary to guide practical dietary strategies.
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